Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells

Biomarker identification for statin sensitivity of cancer cell lines

(2018) Vineet K. Raghu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins

(2018) Federica Iannelli et al.   Recent Patents on Anti-Cancer Drug Discovery

Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells

(2016) Andy Göbel et al.   CANCER LETTERS

The Role of Cholesterol in Cancer

(2016) Omer F. Kuzu et al.   CANCER RESEARCH

High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer

(2016) Siker Kimbung et al.   Oncotarget

Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease

(2016) Valentina Cappello et al.   Scientific Reports

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Mevalonate metabolism in cancer

(2015) Georg Gruenbacher et al.   CANCER LETTERS

Statins are potential anticancerous agents (Review)

(2015) ABDULLAH K. ALTWAIRGI   ONCOLOGY REPORTS

Rapid proteasomal elimination of 3-hydroxy-3-methylglutaryl-CoA reductase by interferon-γ in primary macrophages requires endogenous 25-hydroxycholesterol synthesis

(2015) Hongjin Lu et al.   STEROIDS

Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death

(2015) Aleksandra A. Pandyra et al.   Oncotarget

In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells

(2014) P Jiang et al.   BRITISH JOURNAL OF CANCER

Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop

(2014) Aleksandra Pandyra et al.   CANCER RESEARCH

Oxysterols synergize with statins by inhibiting SREBP-2 in ovarian cancer cells

(2014) Cinzia Casella et al.   GYNECOLOGIC ONCOLOGY

Analysis of TP53 Mutation Status in Human Cancer Cell Lines: A Reassessment

(2014) Bernard Leroy et al.   HUMAN MUTATION

Statins and breast cancer prognosis: evidence and opportunities

(2014) Thomas P Ahern et al.   LANCET ONCOLOGY

Cholesterol and breast cancer pathophysiology

(2014) Erik R. Nelson et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Epigenetic regulation of cholesterol homeostasis

(2014) Steve Meaney   Frontiers in Genetics

Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial

(2013) Olöf Bjarnadottir et al.   BREAST CANCER RESEARCH AND TREATMENT

Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells

(2013) Carolyn A. Goard et al.   BREAST CANCER RESEARCH AND TREATMENT

Controlling Cholesterol Synthesis beyond 3-Hydroxy-3-methylglutaryl-CoA Reductase (HMGCR)

(2013) Laura J. Sharpe et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Statins and cancer: Current and future prospects

(2012) Maja Osmak   CANCER LETTERS

Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway

(2012) William A. Freed-Pastor et al.   CELL

Targeting tumor cell metabolism with statins

(2012) J W Clendening et al.   ONCOGENE

Mevalonate Metabolism Regulates Basal Breast Cancer Stem Cells and Is a Potential Therapeutic Target

(2012) Christophe Ginestier et al.   STEM CELLS

Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors

(2011) Norbert Berndt et al.   Nature Protocols

Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma

(2010) J. W. Clendening et al.   BLOOD

Anticancer Efficacy of Simvastatin on Prostate Cancer Cells and Tumor Xenografts Is Associated with Inhibition of Akt and Reduced Prostate-Specific Antigen Expression

(2010) S. T. Kochuparambil et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Dysregulation of the mevalonate pathway promotes transformation

(2010) J. W. Clendening et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer

(2009) Elisabeth R. Garwood et al.   BREAST CANCER RESEARCH AND TREATMENT

Mutant p53 mediates survival of breast cancer cells

(2009) L Y Lim et al.   BRITISH JOURNAL OF CANCER

Dislocation of HMG-CoA Reductase and Insig-1, Two Polytopic Endoplasmic Reticulum Proteins, En Route to Proteasomal Degradation

(2009) Gil S. Leichner et al.   MOLECULAR BIOLOGY OF THE CELL

The Role of HMGCR Alternative Splicing in Statin Efficacy

(2009) Marisa Wong Medina et al.   TRENDS IN CARDIOVASCULAR MEDICINE